23andMe Investor Presentation Deck

ULBP6 inhibition could benefit patients in broad range of tumor types with neoantigen loss Tumor type HNSC² CESC3 Additional tumor types under CDA 23andMe Tumor ULBP6 +++ 23ME'1473: Tumor Cell Killing-Enhanced Antibody Targets Major Resistance Mechanisms Hampering Immune Oncology Targeting NK cells and NKG2D shows clinical promise +++ +++ Soluble ULBP6 Under CDA Under CDA Under CDA 2HNSC, Head and Neck Squamous Cancer; 3CESC, Cervical Squamous Cell Cancer Loss of antigen presentation¹ ++ +++ +++ ¹Dhatchinamoorthy et al., Front Immunol 2021 Dual MOA achieves synergistic NK activation and tumor cell killing (Mean GFP expression well) NK cell T cell MOA 1 Shed ULBP60 Activating NKG2D receptor NKG2D ligand 60 Time lapsed (hour) 108 Tumor cell MOA 2 Effector enhanced Fc FcyR Surface ULBP6 NK cell MOA1 NKG2D activation MOA2 NKG2D activation + ADCC = 23ME-01473 Effector enhanced 23andMe developed major methodological improvements to targeting ULBP6 External clinical validation: Monotherapy activity observed in NKG2D pathway activator (related mechanism) with complete and partial responses at a tolerable dose in early phase clinical trial4 23andMe '1473 targets the highest affinity NKG2D ligand with a tumor cell killing-enhanced antibody 4Wang, et al., CLN-619 ASCO 2023 Copyright © 2024 23andMe, Inc. 32

View entire presentation